Global Breast Cancer Drugs Market (2016 to 2025) - Featuring Novartis AG, Abbvie, Astrazeneca & Eli Lilly and Company Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Breast Cancer Drugs Market by Drug Type: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 - 2025" report has been added to ResearchAndMarkets.com's offering.

The report covers a forecast and an analysis for the breast cancer drugs market on a global and regional level. The study provides historical data from 2016 to 2018 along with forecast from 2019 to 2025 based on revenue (USD Billion).

The study includes drivers and restraints for the breast cancer drugs market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the breast cancer drugs market on a global and regional level.

The report provides company market share analysis to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research & development, and regional expansion of major participants involved in the market on a global and regional basis.

The study provides a decisive view of the breast cancer drugs market by segmenting the market based on drug type and region. Based on drug type, the market is segmented into chemotherapy drugs, hormone therapy drugs, targeted therapy drugs, and other therapeutic drugs.

Market Insights

Chemotherapy drugs are sub-segmented into anthracyclines, taxanes, antimetabolites, alkylating agents, and epothilones. Anthracyclines segment is split into doxorubicin and epirubicin. Taxanes are split into paclitaxel and docetaxel. Antimetabolites segment is classified into fluorouracil, capecitabine, and gemcitabine. Hormone therapy drugs are classified into selective estrogen-receptor modulators (SERMs), aromatase inhibitors, and other hormonal therapies.

Selective estrogen-receptor modulators segment is further split into tamoxifen, raloxifene, and toremifene. Aromatase inhibitors segment is split into letrozole, anastrozole, and megestrol. Other hormonal therapy drugs include goserelin acetate, fulvestrant, fluoxymesterone etc.

The targeted therapy drugs are classified into monoclonal antibodies (mAbs) and tyrosine kinase inhibitors. Monoclonal antibodies (mAbs) are further split into bevacizumab, trastuzumab, and other mAbs.

The regional segment includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further classification into major countries including the U.S., Canada, Germany, France, UK, China, Japan, India, and Brazil.

Key Topics Covered:

1. Introduction

1.1. Report description and scope

1.2. Research scope

1.3. Research methodology

2. Executive Summary

2.1. Global Breast Cancer Drugs Market Revenue, 2016-2025 (USD Billion)

2.2. Global Breast Cancer Drugs Market: Snapshot

3. Breast Cancer Drugs Market - Industry Dynamics

3.1. Introduction

3.2. Market drivers

3.2.1. Global Breast Cancer Drugs market drivers: Impact analysis

3.2.2. Increasing Prevalence of Breast Cancer

3.2.3. Patent Expiry

3.3. Market Restraints

3.3.1. High Cost of Treatment

3.4. Opportunities

3.4.1. Increasing research and development of novel therapies

3.3. Market Restraints

3.4. Opportunities

3.5. Porter's Five Forces Analysis

3.6. Market attractiveness analysis

4. Global Breast Cancer Drugs Market - Competitive Landscape

4.1. Company Market Share Analysis

4.1.1. Global Breast Cancer Drugs Market: Company Market Share, 2018

4.2. Strategic Development

4.2.1. Acquisitions & Mergers

4.2.2. New Product Launch

4.2.3. Agreements, Partnerships, Collaborations, and Joint Ventures

4.2.4. Research and Development and Regional Expansion

5. Global Breast Cancer Drugs Market - Drug Type Analysis

5.1. Global Breast Cancer Drugs Market: DrugTypeoverview

5.1.1. Global Breast Cancer Drugs Market revenue share, by Drug Type, 2018 and 2025

5.2. Chemotherapy Drugs

5.2.1. Global Breast Cancer Drugs Market for Chemotherapy Drugs, 2016-2025 (USD Billion)

5.3. Hormone Therapy Drugs

5.3.1. Global Breast Cancer Drugs Market for Hormone Therapy Drugs, 2016-2025 (USD Billion)

5.4. Targeted Therapy Drugs

5.4.1. Global Breast Cancer Drugs Market for Targeted Therapy Drugs, 2016-2025 (USD Billion)

5.5. Other Therapeutic Drugs

5.5.1. Global Breast Cancer Drugs Market Other Therapeutic Drugs, 2016-2025 (USD Billion)

6. Global Breast Cancer Drugs Market - Regional Analysis

6.1. Global Breast Cancer Drugs Market: Regional overview

6.2. North America

6.2.1. North America Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)

6.2.2. The U.S.

6.2.2.1. The U.S. Breast Cancer Drugs Market Revenue, by Drug Type, 2016-2025 (USD Billion)

6.2.3. Rest of North America

6.3. Europe

6.4. Asia Pacific

6.5. Latin America

6.6. The Middle East and Africa

7. Company Profile

7.1. F. Hoffmann-La Roche Ltd.

7.1.1. Overview

7.1.2. Financials

7.1.3. Product Portfolio

7.1.4. Business strategy

7.1.5. Recent developments

7.2. Novartis AG

7.3. AbbVie, Inc.

7.4. AstraZeneca

7.5. Eli Lilly and Company

7.6. Celgene Corporation

7.7. Biocon

7.8. Merck & Co., Inc.

7.9. Genzyme Corporation

7.10. Janssen Global Services LLC

7.11. MacroGenics, Inc.

7.12. Celldex Therapeutics

7.13. Onyx Pharmaceuticals Inc.

7.14. BioNumerik Pharmaceuticals, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/3qit84